Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Famvir® from Novartis.
Famvir® (famciclovir) is an antiviral used primarily as a treatment for herpes.
Amit Patel, Atnahs’ Managing Director, comments,
“The acquisition of Famvir® continues our strategy of acquiring and marketing trusted brands, and it reinforces our presence in key markets such as Australia, Russia, Saudi Arabia and the UAE. It is also a key factor in our decision to open our new branch office in Dubai, from which we will market and promote our Middle Eastern business.”
Atnahs is a family-owned specialty pharmaceutical business, focused upon acquiring mature branded medicines out of large cap and specialty pharma and developing its own niche generic medicines. Atnahs has now completed eight major acquisitions since its inception in 2013, and now operates a portfolio of over 18 key medicines across more than 130 markets.
Atnahs is based in Basildon, Copenhagen, Vadodara and Sydney.
Contact: Amit Patel at firstname.lastname@example.org or +44(0)1268 594777